Shufengyayun
Generated by GPT-5-miniExpansion Funnel Raw 41 → Dedup 0 → NER 0 → Enqueued 0
| Shufengyayun | |
|---|---|
| Name | Shufengyayun |
| Type | Herbal formula |
| Origin | Traditional Chinese medicine |
| Introduced | Tang dynasty (traditional attribution) |
| Main ingredients | Multiple herbs |
| Uses | Respiratory infections, influenza-like illness |
Shufengyayun Shufengyayun is a traditional Chinese herbal formula associated with respiratory illness management and seasonal influenza-like syndromes, attributed in folk transmission to compilations from the Tang dynasty and popularized in modern China through patent medicine production and herbal clinics. It is recognized within complementary and alternative medicine circles and features in discussions alongside other Chinese patent medicines, being distributed by commercial manufacturers, traditional pharmacies, and used in integrative settings connected to hospitals and private clinics.
Etymology and Origins
The name derives from syllables used in classical Chinese language nomenclature for herbal prescriptions and poetic labels common in texts from the Tang dynasty and later compilations by physicians of the Song dynasty and Ming dynasty. Transmission of the formula is recorded in regional materia medica and in registers of formulas compiled during the Qing dynasty, while marketing and standardization emerged during the 20th century with pharmaceutical enterprises associated with provincial Chinese hospitals and state-owned pharmaceutical companies. The formula’s evolution reflects the influence of notable physicians and compilers from Shanghan Lun, Li Shizhen, and modern proponents who sought to adapt classical prescriptions to outbreaks such as seasonal influenza pandemic concerns, SARS, and endemic respiratory complaints.
Ingredients and Formulation
Shufengyayun is typically a composite formula consisting of multiple herbal components drawn from classical lists; versions vary by manufacturer and regional tradition. Common botanicals and substances included across preparations have parallels with herbs discussed by Li Shizhen and in the Bencao Gangmu, and may overlap with ingredients used in formulas described in the Treatise on Cold Damage tradition. Individual constituents often named in source lists correspond to herbs cultivated in provinces such as Guangdong, Guangxi, Sichuan, and Yunnan and may be processed according to standards influenced by pharmacopoeias maintained by the Pharmacopoeia of the People's Republic of China and regional pharmacopeial guidance. Variants are manufactured by companies affiliated with municipal hospitals, commercial herbal firms, and state-owned enterprises, leading to marked heterogeneity between registered proprietary products and traditional decoctions.
Traditional Uses and Indications
In folk and clinical practice within settings influenced by Traditional Chinese Medicine, Shufengyayun is indicated for patterns classified under classical diagnostic frameworks used by physicians operating in institutions such as Beijing University of Chinese Medicine clinics, municipal integrative medicine wards, and community herbalists. Indications cited in advertising, patient leaflets, and clinician use include symptomatic relief for presentations resembling acute upper respiratory tract infection, common influenza, sore throat episodes encountered in outpatient clinics, and early-stage febrile illnesses that outpatient practitioners historically associated with exterior syndromes. Use is reported across urban centers like Beijing, Shanghai, Guangzhou, and among diasporic communities with ties to clinics in Taiwan and Hong Kong.
Pharmacology and Mechanism of Action
Pharmacological discussions of Shufengyayun reference in vitro studies, animal models, and phytochemical analyses performed by research groups affiliated with universities such as Peking University, Fudan University, and provincial medical colleges. Investigations commonly assess antiviral, anti-inflammatory, and immunomodulatory effects attributed to classes of phytochemicals present in constituent herbs; these are the subject of studies published by laboratories connected to institutions like Chinese Academy of Sciences, Shanghai Institute of Materia Medica, and hospital research centers. Proposed mechanisms invoked in such literature include inhibition of viral replication in cell culture, suppression of proinflammatory cytokines measured in rodent models, and modulation of innate immune responses; these hypotheses are evaluated alongside controls such as oseltamivir in comparative experimental protocols.
Clinical Evidence and Safety
Clinical evidence comprises a mixture of randomized controlled trials, observational studies, and case series produced by hospital teams from institutions including Zhejiang University School of Medicine, Sun Yat-sen University, and district hospitals. Reported outcomes vary with study design quality; some trials claim reduced symptom duration or improved symptomatic scores when Shufengyayun is added to standard care, but systematic reviewers from academic centers and guideline panels such as those convened by public health authorities urge cautious interpretation due to heterogeneity, risk of bias, and variable outcome measures. Safety reports include routine adverse event monitoring conducted in hospitals and pharmacovigilance records from manufacturers and regulatory bodies; documented events range from mild gastrointestinal discomfort to allergic reactions, and regulators recommend attention to herb–drug interactions in patients receiving concomitant antiviral agents, anticoagulants, or immunomodulatory therapies commonly used in tertiary centers like West China Hospital.
Preparation, Dosage, and Administration
Forms of Shufengyayun available to patients include traditional decoctions prepared by practitioners in clinics associated with colleges such as Nanjing University of Chinese Medicine, granules for reconstitution produced by pharmaceutical firms, and patent capsules or tablets marketed by commercial manufacturers in provinces like Jiangsu, Zhejiang, and Shandong. Recommended dosages vary with formulation: decoctions are typically administered in divided daily doses according to practitioner guidance, granules follow manufacturer instructions, and tablets or capsules are dosed per product labeling, with adjustments advised for pediatric patients, pregnant women, and individuals with chronic diseases managed in specialist clinics at institutions such as Peking Union Medical College Hospital. Clinicians and pharmacists in integrated care settings emphasize using standardized products, checking product monographs, and coordinating with clinicians from infectious disease services when combining with conventional antiviral therapy.